191 related articles for article (PubMed ID: 23565248)
1. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.
Liao Y; Wang B; Huang ZL; Shi M; Yu XJ; Zheng L; Li S; Li L
PLoS One; 2013; 8(4):e60444. PubMed ID: 23565248
[TBL] [Abstract][Full Text] [Related]
2. The Association between Peripheral Th17, Th1, IL-17, and IFN-γ Levels and TACE Response in Patients with Unresectable Hepatocellular Carcinoma with or without Cirrhosis.
Hasan I; Gani RA; Lesmana LA; Kresno SB; Pandelaki J; Suwarto S
Acta Med Indones; 2020 Oct; 52(4):326-333. PubMed ID: 33377877
[TBL] [Abstract][Full Text] [Related]
3. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.
Ren Z; Yue Y; Zhang Y; Dong J; Liu Y; Yang X; Lin X; Zhao X; Wei Z; Zheng Y; Wang T
Front Immunol; 2021; 12():624789. PubMed ID: 33717135
[TBL] [Abstract][Full Text] [Related]
4. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients.
Guan HT; Wang J; Yang M; Song L; Tong XQ; Zou YH
Chin Med J (Engl); 2013; 126(19):3651-5. PubMed ID: 24112158
[TBL] [Abstract][Full Text] [Related]
5. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
6. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
7. Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.
Park H; Jung JH; Jung MK; Shin EC; Ro SW; Park JH; Kim DY; Park JY; Han KH
Hepatol Int; 2020 Mar; 14(2):249-258. PubMed ID: 32072464
[TBL] [Abstract][Full Text] [Related]
8. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma.
Liao J; Xiao J; Zhou Y; Liu Z; Wang C
Mol Med Rep; 2015 Oct; 12(4):6065-71. PubMed ID: 26239573
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
[TBL] [Abstract][Full Text] [Related]
10. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
Pinato DJ; Sharma R
Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
[TBL] [Abstract][Full Text] [Related]
11. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
12. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.
Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215
[TBL] [Abstract][Full Text] [Related]
13. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
14. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
16. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T Cells, IL10 and IL6 in HCV Related Hepatocellular Carcinoma after Transarterial Chemoembolization (TACE).
Hassan EA; Ahmed EH; Nafee AM; El-Gafary N; Hetta HF; El-Mokhtar MA
Egypt J Immunol; 2019 Jan; 26(1):69-78. PubMed ID: 31332997
[TBL] [Abstract][Full Text] [Related]
18. Effect of Transcatheter Arterial Chemoembolization Combined with Argon-Helium Cryosurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Patients.
Huang M; Wang X; Bin H
Cell Biochem Biophys; 2015 Dec; 73(3):787-92. PubMed ID: 27259326
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
